obesity, Medicare

Eli Lilly's obesity drug gets Medicare coverage for sleep apnea
Eli Lilly's popular obesity drug Zepbound can now be covered by government-backed Medicare drug plans, CNBC reported on Wednesday, citing the Centers for Medicare & Medicaid Services.
FDA approves anti-obesity drug as first sleep apnea medication
The Food and Drug Administration on Friday approved Eli Lilly’s anti-obesity drug Zepbound as the first prescription medicine for obstructive sleep apnea, marking a major shift in the treatment of the disorder.
Opinion
Medicare should cover anti-obesity drugs
The Centers for Medicare & Medicaid Services has proposed a rule expanding Medicare and Medicaid patients’ access to anti-obesity drugs such as GLP-1s.
CMS confirms to CNBC Medicare plans can now cover Zepbound for sleep apnea
The Centers for Medicare & Medicaid Services confirmed to CNBC that Medicare drug plans can now cover Eli Lilly’s (LLY) obesity drug
Medicare Expands Coverage of Eli Lilly’s Weight-Loss Drug
Eli Lilly’s popular anti-obesity drug Zepbound could get a sales boost after the U.S. Medicare program decided to pay for its use to treat sleep apnea. The Centers f
Medicare can now cover Eli Lilly’s Zepbound for sleep apnea, CMS says
It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other insurance plans for weight loss.
Lilly’s Obesity Drug Zepbound To Be Key 2025 Health Cost Driver
The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers and ...
Fierce Healthcare1d
Found introducing oral dissolvable GLP-1 tablet at reduced price
Weight management platform Found is today launching oral semaglutide dissolvable tablets for individuals looking for ...
Don’t smirk. Anti-obesity drugs have changed people’s lives.
I applaud the Biden administration’s recent moves to make these anti-obesity drugs more accessible to people on Medicaid and ...
Medscape12d
Novel Anti-obesity Drugs and Plasma Lipids
We believe that over the next 5–10 years new anti-obesity drugs with less adverse side-effects and favorable effects on both lipids and cardiometabolic risk will be introduced in clinical practice.
Global pharma giants push for weight-loss drugs to be added to PBS
Eli Lilly will seek to have Mounjaro listed on the scheme this year. If successful, it would mean taxpayer subsidies for the ...
The Hill10d
RFK Jr. vs. Oz sets up clash on weight loss drug coverage
But a new proposal announced by the Biden administration in November ... But it also comes with a price tag in the tens of ...
Medpage Today on MSN11dOpinion
CMS Moved to Expand Obesity Drug Coverage. Private Insurers Need to Step Up.
This proposed rule signals an important shift in the federal approach to obesity management, aligning with the medical ...
Science Daily3d
Obesity News
2024 — Taking anti-obesity drugs has led some U.S. adults to throw away more food than they tossed before starting the medications, a new study has ...